Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List

On March 22, the 2024 Shanghai Industrial Technology Innovation Conference was held with the theme of "Building the Main Engine of Innovation and Seizing New Opportunities in the Future". At this conference, Medicilon won the "2024 Shanghai Hard Core Technology Enterprises TOP100 List" with its hard-core technology and innovative technology service platform in the preclinical field of biopharmaceutical.

Medicilon once again ranked on the 2024 Shanghai Hard Core Technology Enterprises TOP100 List.webp

As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon has always been committed to exploring hard-core technologies in the biopharmaceutical preclinical field. After 20 years of development, Medicilon now has 84,000 square meters of R&D laboratories and a high-quality R&D team. Through continuous technological innovation and R&D investment, we have conquered the core R&D technologies of new molecular types of drugs such as antibodies, peptides, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, cell & gene therapy (CGT), and established a R&D service platform to empower and accelerate global pharmaceutical innovation. At the same time, Medicilon also has a wealth of innovative drug molecule design technology, relying on computer-aided drug design technology, high-throughput drug discovery technology, and bioelectronic isostere technology to establish a more efficient AI-guided drug design and synthesis platform to help clients improve R&D efficiency and reduce R&D barriers.

It is these hard-core scientific and technological innovation capabilities that have enabled Medicilon to empower 421 IND-approved clinical trials in the biopharmaceutical preclinical field, winning widespread recognition and praise, and attracting the favor of many partners. Looking forward to the future, Medicilon will continue to stride forward on the journey of technological innovation and industrial development, injecting continuous innovative vitality and power into the global biopharmaceutical industry!

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

On July 20, 2020, DAC Biotech’s new ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

Shanghai Medicilon Inc.

搜索此博客